Atossa Therapeutics
ATOS
31 hedge funds and large institutions have $2.6M invested in Atossa Therapeutics in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 7 closing their positions.
3,767% more call options, than puts
Call options by funds: $116K | Put options by funds: $3K
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
1.22% more ownership
Funds ownership: 14.4% → 15.62% (+1.2%)
6% less funds holding
Funds holding: 33 → 31 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
60% less capital invested
Capital invested by funds: $6.52M → $2.6M (-$3.92M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$258K |
| 2 |
BlackRock
New York
|
+$142K |
| 3 |
Renaissance Technologies
New York
|
+$105K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$71K |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$57.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$92.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$42.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$21.3K |
| 4 |
Morgan Stanley
New York
|
-$17.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.54K |
ATOS Hedge Fund Activity: Q2 2026 in Review
31 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2026, worth a combined $2.6M — down 60% from $6.52M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATOS and 5 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was Jane Street, opening a new position worth an estimated $258K. The largest seller was Millennium Management, cutting an estimated $92.2K.
- 31 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2026, down from 33 in Q1 2026.
- Funds reported $2.6M of Atossa Therapeutics stock for Q2 2026, down 60% quarter-over-quarter.
- 5 funds opened new Atossa Therapeutics positions in Q2 2026 and 7 closed out, a net change of -2 holders.
- The largest Atossa Therapeutics buyer in Q2 2026 was Jane Street, an estimated $258K added.
- The largest Atossa Therapeutics seller in Q2 2026 was Millennium Management, an estimated $92.2K sold.
Based on aggregated 13F filings for Q2 2026.